Beam Therapeutics is a clinical-stage biotech with a promising base-editing platform, but its financial profile is dominated by milestone-driven revenue volatility and persistent cash burn. The company's revenue swung from $114.1M in 2025Q4 to $490K in 2026Q2,...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$1.18-6.3% vs -$1.11 | $490,000-97.0% vs $16M |
Q2 2026 May 7, 2026 | -$0.91-4.6% vs -$0.87 | $32M+189.1% vs $11M |
Q1 2026 Feb 24, 2026 | -$0.10+91.2% vs -$1.13 | $114M+877.9% vs $12M |
Q4 2025 Nov 4, 2025 | -$1.10-12.2% vs -$0.98 | $10M-26.6% vs $13M |
Short sellers are making bold bets, and the numbers behind those bets are getting harder to ignore. Pessimism this concentrated can set the stage for sharp reversals, since a heavily shorted stock only needs a piece of good news to send bears scrambling to cover their positions.
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) was the recipient of unusually large options trading on Tuesday. Traders bought 2,316 call options on the company. This represents an increase of approximately 139% compared to the typical daily volume of 968 call options. Beam Therapeutics Trading Down 9.5% Shares of Beam Therapeutics stock opened at
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Benchmark BEAM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Beam Therapeutics Inc. (BEAM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.93 | $2.67B | -32.01 | 120.01% | -57.24% | -8.11% | — | |
| $2.92 | $448.11M | -1.62 | 25.39% | -157.32% | -196.63% | — | |
| $59.03 | $5.69B | -9.12 | -89.97% | -3368.72% | -24.39% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $3.54 | $639.39M | -2.62 | 55.28% | -4613.11% | -188.27% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — |
Beam Therapeutics Inc. (BEAM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Beam Therapeutics Inc. (BEAM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 8, 2026·SEC
May 7, 2026·SEC
Get notified when BEAM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Beam Therapeutics Inc. (BEAM) stock FAQ — growth, dividends, profitability & financials explained
Beam Therapeutics Inc. (BEAM) reported $156.0M in revenue for fiscal year 2025.
Beam Therapeutics Inc. (BEAM) grew revenue by 120.0% over the past year. This is strong growth.
Beam Therapeutics Inc. (BEAM) reported a net loss of $85.4M for fiscal year 2025.
Beam Therapeutics Inc. (BEAM) has a return on equity (ROE) of -8.1%. Negative ROE indicates the company is unprofitable.
Beam Therapeutics Inc. (BEAM) had negative free cash flow of $372.8M in fiscal year 2025, likely due to heavy capital investments.
